Stabilized formulations containing Anti-CD20 x Anti-CD3 bispecific antibodies

PH12022551275B1Active Publication Date: 2026-08-14REGENERON PHARMACEUTICALS INC

0 Cites 0 Cited by

Patent Information

Application Number: PH12022551275
Authority / Receiving Office: PH · PH
Patent Type: Patents
Current Assignee / Owner
Filing Date: 2022-05-24
Publication Date: 2026-08-14
Estimated Expiration: 2042-05-24

Application Information

Patent Timeline

24 May 2022

Application

PH12022551275

14 Aug 2026

Publication

PH12022551275B1

Inventors: CHENG, Yuan; TANG, Xiaolin

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human CD20 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

Need to check novelty before this filing date? Find Prior Art